Abnormal Blood Count $\square\square$ WCC< 3.5 x10⁹/l or **neutrophil** count $< 1.6 \times 10^9 / l$ - stop drug. Inform rheumatology. If the patient is febrile or has other evidence of infection, hospital admission for supportive treatment may be necessary □□MCV – a rise in MCV is common with methotrexate. If MCV > 105 fl. check B12 and folate and treat if low. Methotrexate need not be discontinued \square Platelet count <140 x 10⁹/l stop drug and inform rheumatologist. Bleeding or bruising may require hospitalisation for supportive treatment if severe □□Rapid falls or persistent downward trends in any of these measures, even if still within the normal range, may require dosage reduction **Abnormal LFT's D**ALT and alkaline phosphatase within 2 times the upper limit of the normal are acceptable. However, rapid rises in these enzymes, should be discussed Deteriorating renal function increases the risk of toxicity. Deterioriation in renal function requires closer monitoring and a discussion about dose with the rheumatologist. Patients developing acute renal failure while taking methotrexate should stop the drug and may require folinic acid rescue. Take care when introducing ACE-inhibitors & angiotensin II receptor antagonists **Pregnancy and methotrexate □ □ Men and women** taking methotrexate must avoid pregnancy. Methotrexate should be discontinued for at least 3 months (with continued use of effective contraception) prior to attempting to conceive a child. Where a patient wishes to conceive, alternative treatment should be discussed before the patient stops methotrexate Women taking methotrexate must not breast

feed

Abnormal results and what to do

Surgery and methotrexate

Methotrexate may be continued for most elective surgery. However, some surgeons may choose to stop it 1 week prior to surgery. Rheumatology are happy to advise if there is doubt. Careful attention should be given to the early detection and treatment of infections.

Other adverse drug reactions

- Rashes Where methotrexate is considered the cause the drug withhold the drug and contact the rheumatology team for further advice
- □□Breathlessness may be due to infection or pneumonitis. New, unexplained or worsening breathlessness should be managed by stoppingmethotrexate and obtaining a CXR. Infection should be treated. If there is no evidence of infection or the breathlessness fails to settle the rheumatologist should be informed. Consider admission to hospital if severe.
- □□ Mouth ulcers if numerous or severe, a full blood count should be checked urgently. If white cell or neutrophil count is low hospital admission for supportive treatment may be necessary. For mild cases offer folic acid 5 mg every day except the day of methotrexate

Alcohol and methotrexate

Patients taking methotrexate should limit their alcohol intake to well within recommended drinking limits (maximum of 14 units per week for men and women with at least 2 alcohol free days per week)

Contacting the rheumatologist (GPs and treatment room nurses)

Emergency problems – contact the rheumatologist via the above numbers. If this fails advice may be sought from the on-call physician. When in doubt stop the drug at least temporarily Less urgent problems may be dealt with by:

- Writing or e-mail (using the rheumatology advice inbox) providing CHI number and clinical details
- Rheumatology telephone clinic for GPs Tuesday mornings 11-12.30—01896 826665

Borders Rheumatology Service Borders General Hospital MELROSE TD6 9BS Tel:

01896 826665 (office) 01896 826666 (nurse helpline) E-mail: rheumatology@borders.scot.nhs.uk

RheumatologyAdvice@borders.scot.nhs.uk (for health care professionals only)

Prescribing and Monitoring Guidelines

Methotrexate

Shared Care Guidance for General Practitioners and Practice Nurses

November 2017 (review November 2021)

Patient's name Address

Telephone Number:

case of any uncertainty, such sources should always be consulted week bosing L2.5 ang tabletsonly are liceased for use L2.5 and L	This information is provided as a guide – it does not													
Dossing Dasing tabletsomly are licensed for use Dasing tabletsomly are licensed for use	replace manuals such as the BNF or drug data sheets. In						51							
Dosing Dosing tablets only are licensed for use		Date		НЬ	WCC			ESR	ALT		Urea	Creat		
CD-5 mg tablets only are licensed for use CD-compliant goose is Tompweek, as a single close, at bettime. Maximum dose is 25 mg/week. Dose increases should be no more than every 2 weeks, on medical advice. CD-folia acid Sing/week is given 24 hours after the methotrexate, to reduce the risk of toxicity of without reducing efficacy. Pre-freatment assessment CD-veight, FRC, ESR, U &E's and LFT's CD-chest radiograph CD-chest			week			phils	lets			Phos			next	to patient
□Usual starting dose is 10mg/wesk, us a single dose, at bedtime. Maximum dose is 25mg/wesk. Dose increases should be no more than every 2 weeks, on medical advice □□Folic acid 5mg/wesk is given 24 hours after the methotrextact, to reduce the risk of toxicity of without reducing efficacy □□Folic acid 5mg/wesk is given 24 hours after the methotrextact, to reduce the risk of toxicity of without reducing efficacy □□Folic acid 5mg/wesk is given 24 hours after the methotrextact, to reduce the risk of toxicity of without reducing efficacy □□Folic acid 5mg/wesk is given 24 hours after the methotrextact in the particular of the particular	Dosing												test	
at beddine. Maximum dose is 25mg/weck. Dose increases should be no more than every 2 weeks, on medical advice ————————————————————————————————————	$\square \square 2.5$ mg tablets only are licensed for use													
increases should be no more than every 2 weeks, on medical advice ClFolic acid Smg/week is given 24 hours after the methortexate, to reduce the risk of toxicity of without reducing efficacy Pre-treatment assessment ClWeight, FBC, ESR, U &FS and LFT's ClChest radiograph ClBood horne virus screening ClZoster antibody status (if positive no specific precautions required if the patient is exposed to somebody with chickenpox or shingles) Monitoring ClFBC, eGFR, & LFTs 2 - weekly until the dose has been stable for 6 weeks, revert to this schedule after any dose increase ClThereafter monthly PBC, eGFR, & LFTs for 3 months Thereafter monthly PBC, eGFR, & LFTs for 3 months Thereafter the frequency of monitoring may reduce to every 3 months at the discretion of the rhounatologist ClCo-trimoxacole and trimethoprim are folate antagonists and must not be prescribed with methotrexate ClCo-trimoxacole and trimethoprim are folate antagonists and must not be prescribed with caution where there is a destrication in renal function ClPbentypion, follobatmicke, probenecid and pencicl—fin may increase methortexate felvels and monitoring should be increased if given long term ACE inhibitors and angionens in If receptor antagonists can reduce renal clearance of methorexate particularly in the context of delaydration. Patients should stop these drugs and methorexate if they have diarhorea and/or	□□Usual starting dose is 10mg/week, as a single dose,													
medical advice LiFolica acid Smyweek is given 24 hours after the methotrexate, to reduce the risk of toxicity of without reducing efficacy Pre-freatment assessment Li Weight, FBC, FSR, U &F's and LFT's Li Chest radiograph Blood borne virus screning LiZoster antibody status (if positive no specific precautions required if the patient is exposed to somebody with chickenpox or shingles) Monitoring LiFBC, eGFR & LFTs 2-weekly until the dose has been stable for 6 weeks, revert to this schedule after any dose increase LiThereafter monthly FBC, eGFR & LFTs for 3 months Thereafter the frequency of monitoring may reduce to every 3 months at the discretion of the rheumatologist Drug interactions with Methotrexate LiCo-trimoxazole and trimethoprim are folate antagonists and must not be prescribed with methotrexate (INon-steroidal anti-inflammatory drugs do not need to he discontinued, though should be used with caution where there is a deterioration in renal function LiPhenytoin, tolobarnide, probenecid and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dely/dration. Patients should stop these drugs and methotrexate if they have claim-offender and or drugs and methortexate if they have claim-offender and or drugs and methortexate if they have claim-offender and or drugs and methortexate if they have claim-offender and or drugs and methortexate if they have claim-offender and or drugs and methortexate if they have claim-offender and or drugs and methortexate if they have claim-offender and or drugs and methortexate if they have claim-offender and or drugs and methor and or drugs and method and o	at bedtime. Maximum dose is 25mg/week. Dose													
□ Folic acid Smg/week is given 24 hours after the methortexate, to reduce the risk of toxicity of without reducing efficacy Pre-treatment assessment □ Weight, FBC, ESR U &E's and LFT's □ Closter and tograph □ Blood borne virus screening □ Closter antibody status (if positive no specific precautions required if the patient is exposed to somebody with chickenpox or shingles) Monitoring □ FBC, eGFR & LFTs 2-weekly until the dose has been stable for 6 weeks, revert to this schedule after any dose increase □ Thereafter monthly FBC, eGFR & LFTs for 3 months □ Thereafter the frequency of monitoring may reduce to every 3 months at the discretion of the rheumatologist Drug interactions with Methotrexate □ Co-trimoxazole and trimethoprim are folate antagonists and must not be prescribed with methotrexate is also and the discretion of the rheumatologist of the properties														
methotrexate, to reduce the risk of toxicity of without reducing efficacy Pre-treatment assessment Weight, FBC, ESR, U &E's and LFT's Chest radiograph Blood borne virus screening Pro-treatment assessment Moster antibody status (if positive no specific precautions required if the patient is exposed to somebody with chickenpox or shingles) Monitoring FBC, eGFR & LFTs 2-weekly until the dose has been stable for 6 weeks, revert to this schedule after any dose increase Thereafter monthly FBC, eGFR & LFTs for 3 months Thereafter the frequency of monitoring may reduce to every 3 months at the discretion of the rheumatologist Drug interactions with Methotrexate Co-trimoxazole and trimethoprim are folate antagonists and must not be prescribed with methotrexate Non-steroidal anti-inflammatory drugs do not need to be discontinued, though should be used with caution where there is a deterioration in renaf function Chephenytoin, tolbustmide, probenecid and penicil- lin may increase methorexate levels and monitoring should be increased if given long term ACE inhibitors and angionens in It receptor antagonists can reduce renal elearnace of methotrexate particularly in the context of dichydration. Patients should stop these drugs and methorexate if they have diamboa and/or														
Pre-freatment assessment □ Weight, PBC, ESR, U &F's and LFT's □ Chest radiograph □ Zoster antibody status (if positive no specific precautions required if the patient is exposed to somebody with chickenpox or shingles) Monitoring □ FBC, GGFR & LFTs 2-weekly until the dose has been stable for 6 weeks, revert to this schedule after any dose increase □ Thereafter monthly FBC, GGFR & LFTs for 3 months □ Thereafter the frequency of monitoring may reduce to every 3 months at the discretion of the theumatologist Drug interactions with Methotrexate □ Co-trimoxazole and trimethoprim are folate antagonistis and must not be prescribed with methotrexate □ Non-steroidal anti-inflammatory drugs do not need to be discontinued, though should be used with caution where there is a deterioration in rena function □ Phenytoin, tolbuatmide, probenecid and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term □ ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearnace of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methorexate if they have diarrhece and/or														
Pre-treatment assessment Weight, FBC, FSR, U &E's and LFT's														
□ Chest radiograph □ Blood borne virus screening □ Zoster antibody status (if positive no specific precautions required if the patient is exposed to somebody with chickenpox or shingles) Monitoring □ FBC, eGFR & LFTs 2- weekly until the dose has been stable for 6 weeks, revert to this schedule after any dose increase □ Thereafter monthly FBC, eGFR & LFTs for 3 months □ Thereafter the frequency of monitoring may reduce to every 3 months at the discretion of the rheumatologist Drug interactions with Methotrexate □ Co-trimoxazode and trimethoprim are folate antagonistis and must not be prescribed with methotrexate □ Non-steroidal anti-inflammatory drugs do not need to be discontinued, though should be used with caution where there is a deterioration in renal function □ Phenytoin, tolbuatmide, probenecid and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methorexate if they have diarrhoea and/or	reducing efficacy													
□ Chest radiograph □ Blood borne virus screening □ Zoster antibody status (if positive no specific precautions required if the patient is exposed to somebody with chickenpox or shingles) Monitoring □ FBC, eGFR & LFTs 2- weekly until the dose has been stable for 6 weeks, revert to this schedule after any dose increase □ Thereafter monthly FBC, eGFR & LFTs for 3 months □ Thereafter the frequency of monitoring may reduce to every 3 months at the discretion of the rheumatologist Drug interactions with Methotrexate □ Co-trimoxazode and trimethoprim are folate antagonistis and must not be prescribed with methotrexate □ Non-steroidal anti-inflammatory drugs do not need to be discontinued, though should be used with caution where there is a deterioration in renal function □ Phenytoin, tolbuatmide, probenecid and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methorexate if they have diarrhoea and/or	P. 4 4 4													
□ Blood borne virus screening □ Zoster antibody status (if positive no specific precautions required if the patient is exposed to somebody with chickenpox or shingles) Monitoring □ FBC, eGFR & LFTs 2 - weekly until the dose has been stable for 6 weeks, revert to this schedule after any dose increase □ Thereafter monthly FBC, eGFR & LFTs for 3 months □ Thereafter the frequency of monitoring may reduce to every 3 months at the discretion of the rheumatologist □ Co-trimoxazole and trimethoprim are folate antagonistis and must not be prescribed with methotrexate □ Non-steroidal anti-inflammatory drugs do not need to be discontinued, though should be used with caution where there is a deterioration in renal function □ Phenytoin, tolbuatmide, probenecid and penicil—lin may increase methotrexate levels and monitoring should be increased if given long term ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhose and/or														
□ Blood borne virus screening □ □ Coster antibody status (if positive no specific precautions required if the patient is exposed to somebody with chickenpox or shingles) Monitoring □ □ FBC, eGFR & LFTs 2-weekly until the dose has been stable for 6 weeks, revert to this schedule after any dose increase □ □ Thereafter monthly FBC, eGFR & LFTs for 3 months □ Thereafter the frequency of monitoring may reduce to every 3 months at the discretion of the rheumatologist □ Thereafter with Methotrexate □ Co-trimoxazole and trimethoprim are folate antagonistis and must not be prescribed with methotrexate □ □ Non-steroidal anti-inflammatory drugs do not need to be discontinued, though should be used with caution where there is a deterioration in renal function □ □ Phenytoin, tolbustmide, probenecid and pericil- lin may increase methotrexate levels and monitoring should be increased if given long term ACE inhibitors and angionesm if I receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoea and/or														
Doug interactions with Methotrexate Drug interactions with Methotrexate Doug interactions with methotrexate Doug interactions with methotrexate Doug interaction with ording in may increase enthotrexate levels and monitoring should be increase entrugs and methorexate levels and monitoring should be increase entrugs and methorexate levels and monitoring should be increase entrugs and methorexate levels and monitoring should be increase entrugs and methotrexate levels and monitoring should be increased if given long term Doug interactions with methotrexate Doug interactions with method interactions with														
specific precautions required if the patient is exposed to somebody with chickenpox or shingles) Monitoring BBC, eGFR & LFTs 2- weekly until the dose has been stable for 6 weeks, revert to this schedule after any dose increase Thereafter monthly FBC, eGFR & LFTs for 3 months at the discretion of the rheumatologist Thereafter the frequency of monitoring may reduce to every 3 months at the discretion of the rheumatologist Drug interactions with Methotrexate Co-trimoxazole and trimethoprim are folate antagonistis and must not be prescribed with methotrexate Non-steroidal anti-inflammatory drugs do not need to be discontinued, though should be used with caution where there is a deterioration in renal function Phenytoin, tolbuatmide, probenecid and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these durys and methotrexate if they have diarrhoca and/or														
patient is exposed to somebody with chickenpox or shingles) Monitoring □BC, eGFR & LFTs 2-weekly until the dose has been stable for 6 weeks, revert to this schedule after any dose increase □Thereafter monthly FBC, eGFR & LFTs for 3 months □Thereafter the frequency of monitoring may reduce to every 3 months at the discretion of the rheumatologist Drug interactions with Methotrexate □Co-trimoxazole and trimethoprim are folate antagonists and must not be prescribed with methotrexate □Non-steroidal anti-inflammatory drugs do not need to be discontinued, though should be used with caution where there is a deterioration in renal function □Phenytoin, tobluatmide, probenecid and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoca and/or														
Chickenpox or shingles) Monitoring BBC, eGFR & LFTs 2-weekly until the dose has been stable for 6 weeks, revert to this schedule after any dose increase Thereafter monthly FBC, eGFR & LFTs for 3 months Thereafter the frequency of monitoring may reduce to every 3 months at the discretion of the rheumatologist Drug interactions with Methotrexate Co-trimoxazole and trimethoprim are folate antagonistis and must not be prescribed with methotrexate Non-steroidal anti-inflammatory drugs do not need to be discontinued, though should be used with caution where there is a deterioration in renal function DPhenytoin, tolbuarmide, probenecial and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoea and/or														
□FBC, eGFR & LFTs 2-weekly until the dose has been stable for 6 weeks, revert to this schedule after any dose increase □Thereafter monthly FBC, eGFR & LFTs for 3 months □Thereafter the frequency of monitoring may reduce to every 3 months at the discretion of the rheumatologist Drug interactions with Methotrexate □Co-trimoxazole and trimethoprim are folate antagonistis and must not be prescribed with methotrexate □Non-steroidal anti-inflammatory drugs do not need to be discontinued, though should be used with caution where there is a deterioration in renal function □Phenytoin, tolbuatmide, probenecid and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term □ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoca and/or														
□FBC, eGFR & LFTs 2-weekly until the dose has been stable for 6 weeks, revert to this schedule after any dose increase □Thereafter monthly FBC, eGFR & LFTs for 3 months □Thereafter the frequency of monitoring may reduce to every 3 months at the discretion of the rheumatologist Drug interactions with Methotrexate □Co-trimoxazole and trimethoprim are folate antagonistis and must not be prescribed with methotrexate □Non-steroidal anti-inflammatory drugs do not need to be discontinued, though should be used with caution where there is a deterioration in renal function □Phenytoin, tolbuatmide, probenecid and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term □ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoca and/or														
been stable for 6 weeks, revert to this schedule after any dose increase Thereafter monthly FBC, eGFR & LFTs for 3 months Thereafter the frequency of monitoring may reduce to every 3 months at the discretion of the rheumatologist Drug interactions with Methotrexate Co-trimoxazole and trimethoprim are folate antagonistis and must not be prescribed with methotrexate Non-steroidal anti-inflammatory drugs do not need to be discontinued, though should be used with caution where there is a deterioration in renal function Phenytoin, tolbuatmide, probenecid and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoea and/or	Monitoring													
any dose increase Thereafter monthly FBC, eGFR & LFTs for 3 months Thereafter the frequency of monitoring may reduce to every 3 months at the discretion of the rheumatologist Drug interactions with Methotrexate Co-trimoxazole and trimethoprim are folate antagonistis and must not be prescribed with methotrexate Non-steroidal anti-inflammatory drugs do not need to be discontinued, though should be used with caution where there is a deterioration in renal function Phenytoin, tolbuatmide, probenecid and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarnhoea and/or	· · · · · · · · · · · · · · · · · · ·													
Thereafter monthly FBC, eGFR & LFTs for 3 months Thereafter the frequency of monitoring may reduce to every 3 months at the discretion of the rheumatologist Drug interactions with Methotrexate Co-trimoxazole and trimethoprim are folate antagonistis and must not be prescribed with methotrexate Non-steroidal anti-inflammatory drugs do not need to be discontinued, though should be used with caution where there is a deterioration in renal function Phenytoin, tolbuatmide, probenecid and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoea and/or														
months Thereafter the frequency of monitoring may reduce to every 3 months at the discretion of the rheumatologist Drug interactions with Methotrexate Co-trimoxazole and trimethoprim are folate antagonistis and must not be prescribed with methotrexate Non-steroidal anti-inflammatory drugs do not need to be discontinued, though should be used with caution where there is a deterioration in renal function Phenytoin, tolbuatmide, probenecid and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoea and/or														
□ Thereafter the frequency of monitoring may reduce to every 3 months at the discretion of the rheumatologist Drug interactions with Methotrexate □ Co-trimoxazole and trimethoprim are folate antagonistis and must not be prescribed with methotrexate □ Non-steroidal anti-inflammatory drugs do not need to be discontinued, though should be used with caution where there is a deterioration in renal function □ Phenytoin, tolbuatmide, probenecid and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term □ ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoea and/or														
to every 3 months at the discretion of the rheumatologist Drug interactions with Methotrexate Co-trimoxazole and trimethoprim are folate antagonistis and must not be prescribed with methotrexate Non-steroidal anti-inflammatory drugs do not need to be discontinued, though should be used with caution where there is a deterioration in renal function Phenytoin, tolbuatmide, probenecid and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoea and/or														
rheumatologist Drug interactions with Methotrexate Co-trimoxazole and trimethoprim are folate antagonistis and must not be prescribed with methotrexate Non-steroidal anti-inflammatory drugs do not need to be discontinued, though should be used with caution where there is a deterioration in renal function Phenytoin, tolbuatmide, probenecid and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoea and/or														
Drug interactions with Methotrexate Co-trimoxazole and trimethoprim are folate antagonistis and must not be prescribed with methotrexate Non-steroidal anti-inflammatory drugs do not need to be discontinued, though should be used with caution where there is a deterioration in renal function Phenytoin, tolbuatmide, probenecid and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoea and/or														
□Co-trimoxazole and trimethoprim are folate antagonistis and must not be prescribed with methotrexate □Non-steroidal anti-inflammatory drugs do not need to be discontinued, though should be used with caution where there is a deterioration in renal function □Phenytoin, tolbuatmide, probenecid and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoea and/or	meumatologist													
□Co-trimoxazole and trimethoprim are folate antagonistis and must not be prescribed with methotrexate □Non-steroidal anti-inflammatory drugs do not need to be discontinued, though should be used with caution where there is a deterioration in renal function □Phenytoin, tolbuatmide, probenecid and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoea and/or	Drug interactions with Methotrexate													
antagonistis and must not be prescribed with methotrexate Non-steroidal anti-inflammatory drugs do not need to be discontinued, though should be used with caution where there is a deterioration in renal function Phenytoin, tolbuatmide, probenecid and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoea and/or														
□ Non-steroidal anti-inflammatory drugs do not need to be discontinued, though should be used with caution where there is a deterioration in renal function □ Phenytoin, tolbuatmide, probenecid and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term □ ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoea and/or														
need to be discontinued, though should be used with caution where there is a deterioration in renal function Phenytoin, tolbuatmide, probenecid and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoea and/or	methotrexate													
caution where there is a deterioration in renal function □ Phenytoin, tolbuatmide, probenecid and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoea and/or	□□Non-steroidal anti-inflammatory drugs do not													
□□Phenytoin, tolbuatmide, probenecid and penicil- lin may increase methotrexate levels and monitoring should be increased if given long term □ ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoea and/or														
may increase methotrexate levels and monitoring should be increased if given long term ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoea and/or														
should be increased if given long term ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoea and/or														
ACE inhibitors and angiotensin II receptor antagonists can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoea and/or														
can reduce renal clearance of methotrexate particularly in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoea and/or														
in the context of dehydration. Patients should stop these drugs and methotrexate if they have diarrhoea and/or														
drugs and methotrexate if they have diarrhoea and/or														
VO(1111110)	vomiting													